UroMems
PrivateLast Round
Strategic
May 13, 2026
Total Funding Raised
$168.27M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
UroMems operates in Healthcare & Life Sciences and is based in Eybens. Its latest recorded funding round was a Strategic round in May 2026.
UroMems is a medical device company that specializes in the design, development, and commercialization of active implantable devices for the treatment of stress urinary incontinence.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
UroMems Comparables
Compare UroMems with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Affluent Medical | 90% | |
| Rigicon, Inc. | 84% | |
| Zephyr Surgical Implants | 82% |
For institutional investors. Book with your work email.
UroMems Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | May 13, 2026 | ||||
| Series C | Jun 25, 2024 | ||||
| Grant | Nov 13, 2023 | ||||
| Series B | Apr 20, 2021 | ||||
| Series B | May 20, 2020 | ||||
Series A | Nov 15, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
UroMems Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series C |
| European Commission (Horizon Europe) | Series C |
| Ajax Health | Strategic |
| Montpensier Arbevel | Series C, Series B |
| Banque Populaire | Series B |
| Supernova Invest | Series B, Series C, Series A |
| Crédit Mutuel Innovation | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 50% MoM.
- Jul 26, 2026
Monthly visitors increased 65% MoM.
For institutional investors. Book with your work email.
UroMems Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about UroMems's valuation, stock price, and market status.
Is UroMems a public or private company?
UroMems is a private company.
What is the current stock price of UroMems?
UroMems is a private company, so its shares have no public market price. Caplight tracks UroMems's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is UroMems worth (valuation)?
Valuation information for UroMems is not publicly available.
Can I buy UroMems stock?
UroMems shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was UroMems's last funding round?
UroMems's most recent funding round was Strategic on May 13, 2026.
Who are the main investors in UroMems?
Key investors in UroMems include Ajax Health, Montpensier Arbevel, Crédit Mutuel Innovation, Hil Invent, Wellington Partners.
Will UroMems IPO soon?
No public IPO plans have been announced for UroMems.
How can I track UroMems secondary market activity?
Caplight tracks bids, offers, and trades in UroMems's shares on secondary markets.